单剂唑来膦酸在第二疗程罗莫索单抗后维持骨密度达2年
这项2期剂量探索研究纳入低骨量绝经后女性,评估罗莫索单抗治疗后转用唑来膦酸的疗效与安全性。单剂5 mg唑来膦酸一般能维持罗莫索单抗治疗获得的骨密度增益,且耐受性良好。
要点
- 罗莫索单抗治疗后需后续抗吸收治疗以维持骨骼获益。
- 单剂5 mg唑来膦酸一般能维持罗莫索单抗获得的骨密度增益。
- 单剂5 mg唑来膦酸耐受性良好,未观察到新的安全性信号。
核心结论
- 唑来膦酸后续治疗方案能维持罗莫索单抗治疗获得的稳健骨密度增益。
研究设计与样本
- 这项2期剂量探索研究纳入低骨密度绝经后女性。
- 受试者在0-24个月接受不同剂量罗莫索单抗或安慰剂,随后12个月随机接受地舒单抗60 mg皮下注射每6个月一次或安慰剂,之后12个月开放标签罗莫索单抗210 mg每月一次。
- 第48个月时,已接受48个月活性治疗的受试者分配至不再接受活性治疗组,其余所有受试者分配至唑来膦酸5 mg静脉注射组,评估24个月至第72个月。
主要发现
- 共141名受试者进入第48-72个月期间,其中不再接受活性治疗组51名,唑来膦酸组90名。
- 不再接受活性治疗组腰椎骨密度从第48-72个月下降10.8%,但仍比原始基线高4.2%。
- 唑来膦酸组腰椎骨密度得以维持(第48-72个月变化-0.8%;第0-72个月变化12.8%)。
- 两组近端股骨骨密度观察到相似模式。
- 不再接受活性治疗组P1NP和β-CTX下降,但第72个月时仍高于基线;唑来膦酸组P1NP和β-CTX初始下降,但至第72个月时接近基线。
关键数值与推荐
- 唑来膦酸组腰椎骨密度第48-72个月变化-0.8%,第0-72个月变化12.8%。
- 不再接受活性治疗组腰椎骨密度第48-72个月下降10.8%,第72个月时仍比原始基线高4.2%。
临床怎么用
- 唑来膦酸后续治疗方案可维持罗莫索单抗治疗获得的稳健骨密度增益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This phase 2 study evaluated the efficacy and safety of transitioning to zoledronate following romosozumab treatment in postmenopausal women with low bone mass. A single dose of 5 mg zoledronate generally maintained the robust BMD gains accrued with romosozumab treatment and was well tolerated. INTRODUCTION: Follow-on therapy with an antiresorptive agent is necessary to maintain the skeletal benefits of romosozumab therapy. We evaluated the use of zoledronate following romosozumab treatment. METHODS: This phase 2, dose-finding study enrolled postmenopausal women with low bone mineral density (BMD). Subjects who received various romosozumab doses or placebo from months 0-24 were rerandomized to denosumab (60 mg SC Q6M) or placebo for 12 months, followed by open-label romosozumab (210 mg QM) for 12 months. At month 48, subjects who had received active treatment for 48 months were assigned to no further active treatment and all other subjects were assigned to zoledronate 5 mg IV. Efficacy (BMD, P1NP, and β-CTX) and safety were evaluated for 24 months, up to month 72. RESULTS: A total of 141 subjects entered the month 48-72 period, with 51 in the no further active treatment group and 90 in the zoledronate group. In subjects receiving no further active treatment, lumbar spine (LS) BMD decreased by 10.8% from months 48-72 but remained 4.2% above the original baseline. In subjects receiving zoledronate, LS BMD was maintained (percentage changes: - 0.8% from months 48-72; 12.8% from months 0-72). Similar patterns were observed for proximal femur BMD in both groups. With no further active treatment, P1NP and β-CTX decreased but remained above baseline at month 72. Following zoledronate, P1NP and β-CTX levels initially decreased but approached baseline by month 72. No new safety signals were observed. CONCLUSION: A zoledronate follow-on regimen can maintain robust BMD gains achieved with romosozumab treatment.
引用
- McClung MR, Bolognese MA, Brown JP, et al. A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab. Osteoporos Int. 2020. PMID: 32623487. doi:10.1007/s00198-020-05502-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。